SCM
NVCR icon

Superstring Capital Management’s NovoCure NVCR Stock Holding History

Superstring Capital Management’s Portfolio NVCR Stock Details NVCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-286,970
Closed -$8.55M – 45
2024
Q4 		$8.55M Sell
286,970
-105,741
-27% -$2.24M 7.41% 4
2024
Q3 		$6.14M Buy
392,711
+325,819
+487% +$5.91M 5.37% 7
2024
Q2 		$1.15M Buy
+66,892
New +$1.18M 1.44% 20

Other funds holding NVCR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Superstring Capital Management's NVCR Position: Q1 2025 in Review

Superstring Capital Management sold out of NovoCure (NVCR) in Q1 2025, closing a stake of 286,970 shares — an estimated $8.55M sold.

Superstring Capital Management first reported a position in NVCR in Q2 2024 and held it in 3 quarters. The position peaked at $8.55M in Q4 2024. 227 funds tracked by Wall St. Rank hold NVCR as of Q1 2025.

  • Superstring Capital Management reported no remaining NovoCure position as of Q1 2025 after selling out during the quarter.
  • Superstring Capital Management sold 286,970 NovoCure shares in Q1 2025, an estimated $8.55M.
  • Superstring Capital Management first reported a position in NovoCure in Q2 2024 and held it in 3 quarters.
  • Superstring Capital Management's NovoCure position peaked at $8.55M in Q4 2024.
  • 227 funds tracked by Wall St. Rank held NovoCure as of Q1 2025.

Based on Superstring Capital Management's 13F filing for Q1 2025, filed 15 May 2025.